Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) Income towards Parent Company: 2019-2025

Historic Income towards Parent Company for BridgeBio Pharma (BBIO) over the last 7 years, with Sep 2025 value amounting to -$184.9 million.

  • BridgeBio Pharma's Income towards Parent Company fell 12.59% to -$184.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$763.1 million, marking a year-over-year decrease of 85.40%. This contributed to the annual value of -$543.3 million for FY2024, which is 16.82% up from last year.
  • According to the latest figures from Q3 2025, BridgeBio Pharma's Income towards Parent Company is -$184.9 million, which was down 9.04% from -$169.6 million recorded in Q2 2025.
  • BridgeBio Pharma's Income towards Parent Company's 5-year high stood at -$19.1 million during Q1 2024, with a 5-year trough of -$267.4 million in Q4 2024.
  • Moreover, its 3-year median value for Income towards Parent Company was -$164.3 million (2024), whereas its average is -$150.3 million.
  • As far as peak fluctuations go, BridgeBio Pharma's Income towards Parent Company skyrocketed by 86.59% in 2024, and later crashed by 640.71% in 2025.
  • Quarterly analysis of 5 years shows BridgeBio Pharma's Income towards Parent Company stood at -$180.6 million in 2021, then increased by 19.62% to -$145.1 million in 2022, then crashed by 32.37% to -$192.1 million in 2023, then crashed by 39.19% to -$267.4 million in 2024, then declined by 12.59% to -$184.9 million in 2025.
  • Its last three reported values are -$184.9 million in Q3 2025, -$169.6 million for Q2 2025, and -$141.1 million during Q1 2025.